International Dosimetry Exchange for Boron Neutron Capture Therapykent.riley
The document discusses the potential for a more formal collaboration between BNCT clinical centers to collectively analyze clinical outcomes data. It proposes that a coordinated effort could help advance the field by increasing patient statistics, standardizing practices, and facilitating comparisons to other treatments. Previous informal cooperation between centers has been successful, and a more organized international initiative modeling existing efforts like the International Dosimetry Exchange could provide insights to optimize protocols and assess normal tissue tolerances.
The document summarizes the history and development of Boron Neutron Capture Therapy (BNCT) for cancer treatment. It discusses how boron is used to selectively target cancer cells and how neutron capture by boron leads to high-LET particle production within tumor cells. Key developments include the first studies in the 1930s, clinical trials starting in the 1980s focused on glioblastoma, and ongoing research to develop more effective boron delivery agents and dosimetry techniques. BNCT shows potential for treating cancers like brain tumors but challenges remain around boron delivery and normal tissue toxicity.
Neutron capture therapy is a binary system that consists of two separate components to achieve its therapeutic effect. Each component in itself is non-tumoricidal, but when combined together they are highly lethal to cancer cells.BNCT is based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which makes up approximately 20% of natural elemental boron, is irradiated with neutrons of the appropriate energy to yield excited boron-11 (11B*). This undergoes instantaneous nuclear fission to produce high-energy alpha particles (4He nuclei) and high-energy lithium-7 (7Li) nuclei. BNCT bestows upon the nuclear reaction that occurs when Boron-10, a stable isotope, is irradiated with low-energy thermal neutrons to yield α particles (Helium-4) and recoiling lithium-7 nuclei. • The unique property of BNCT is that it can deposit a large dose gradient between the tumour cells and normal cells.
The selective delivery of sufficient amounts of 10B to the tumor with only small amounts localized in the surrounding normal tissues.Thus, normal tissues, if they have not taken up sufficient amounts of boron-10, can be spared from the nuclear capture and fission reactions. Normal tissue tolerance is determined by the nuclear capture reactions that occur with normal tissue hydrogen and nitrogen.
BNCT, therefore, can be regarded as both a biologically and a physically targeted type of radiation therapy.
This document discusses various particle beams used in radiation therapy, including their properties and effectiveness. It states that proton beams have superior dose distribution compared to photon beams but lower LET. Neutron beams have high LET properties but poor dose distribution. Heavy charged particle beams like carbon ions have both superior distribution and high LET. BNCT uses boron compounds and neutrons to specifically target tumor cells but is limited by availability and cost. Overall, the document provides an overview of different particle therapies and their advantages over conventional photon radiation.
Particle beam – proton,neutron & heavy ion therapyAswathi c p
particle therapy is advanced external beam therapy used to treat cancer , which uses beams of protons or other charged particles such as helium, carbon or other ions instead of photons. charged particles have different depth-dose distributions compared to photons. They deposit most of their energy in the last final millimeters of their trajectory (when their speed slows). This results in a sharp and localized peak of dose, known as the Bragg peak.
Proton beam therapy for tumors of skull baseTehreem Khan
This document discusses proton beam therapy for treating skull base tumors. It begins with an overview of brain tumors and skull base anatomy. It then discusses how tumors are diagnosed and different radiation therapy options. Proton beam therapy is introduced as an advanced form of radiation therapy that uses proton beams to damage tumor DNA. Key advantages are its ability to deposit most energy in the tumor while minimizing damage to surrounding healthy tissue. The document provides background on proton physics and accelerators used in therapy. It concludes proton beam therapy has been safely and effectively used in thousands of patients with various cancer types.
This document discusses radiation therapy for cancer treatment. It describes how the type of cancer, efficacy of other treatments, and patient health determine whether radiation therapy is used. Radiation therapy aims to kill cancer cells using high energy x-rays directed at tumors. Treatment planning involves outlining tumor volumes and minimizing dose to healthy tissues. Radiation damages DNA and prevents cell division, preferentially killing cancer cells. Modern linear accelerators precisely deliver megavoltage x-rays while minimizing surface dose. Treatment techniques like IMRT further improve targeting and reduce side effects.
The International Agency for Research on Cancer projects that by 2030 almost 21.4 million new cancer cases will be diagnosed annually, a sharp rise from the estimated 12.7 million new cases in 2008. The agency predicts that cancer rates will continue rising as populations increase and expand in developing nations.
International Dosimetry Exchange for Boron Neutron Capture Therapykent.riley
The document discusses the potential for a more formal collaboration between BNCT clinical centers to collectively analyze clinical outcomes data. It proposes that a coordinated effort could help advance the field by increasing patient statistics, standardizing practices, and facilitating comparisons to other treatments. Previous informal cooperation between centers has been successful, and a more organized international initiative modeling existing efforts like the International Dosimetry Exchange could provide insights to optimize protocols and assess normal tissue tolerances.
The document summarizes the history and development of Boron Neutron Capture Therapy (BNCT) for cancer treatment. It discusses how boron is used to selectively target cancer cells and how neutron capture by boron leads to high-LET particle production within tumor cells. Key developments include the first studies in the 1930s, clinical trials starting in the 1980s focused on glioblastoma, and ongoing research to develop more effective boron delivery agents and dosimetry techniques. BNCT shows potential for treating cancers like brain tumors but challenges remain around boron delivery and normal tissue toxicity.
Neutron capture therapy is a binary system that consists of two separate components to achieve its therapeutic effect. Each component in itself is non-tumoricidal, but when combined together they are highly lethal to cancer cells.BNCT is based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which makes up approximately 20% of natural elemental boron, is irradiated with neutrons of the appropriate energy to yield excited boron-11 (11B*). This undergoes instantaneous nuclear fission to produce high-energy alpha particles (4He nuclei) and high-energy lithium-7 (7Li) nuclei. BNCT bestows upon the nuclear reaction that occurs when Boron-10, a stable isotope, is irradiated with low-energy thermal neutrons to yield α particles (Helium-4) and recoiling lithium-7 nuclei. • The unique property of BNCT is that it can deposit a large dose gradient between the tumour cells and normal cells.
The selective delivery of sufficient amounts of 10B to the tumor with only small amounts localized in the surrounding normal tissues.Thus, normal tissues, if they have not taken up sufficient amounts of boron-10, can be spared from the nuclear capture and fission reactions. Normal tissue tolerance is determined by the nuclear capture reactions that occur with normal tissue hydrogen and nitrogen.
BNCT, therefore, can be regarded as both a biologically and a physically targeted type of radiation therapy.
This document discusses various particle beams used in radiation therapy, including their properties and effectiveness. It states that proton beams have superior dose distribution compared to photon beams but lower LET. Neutron beams have high LET properties but poor dose distribution. Heavy charged particle beams like carbon ions have both superior distribution and high LET. BNCT uses boron compounds and neutrons to specifically target tumor cells but is limited by availability and cost. Overall, the document provides an overview of different particle therapies and their advantages over conventional photon radiation.
Particle beam – proton,neutron & heavy ion therapyAswathi c p
particle therapy is advanced external beam therapy used to treat cancer , which uses beams of protons or other charged particles such as helium, carbon or other ions instead of photons. charged particles have different depth-dose distributions compared to photons. They deposit most of their energy in the last final millimeters of their trajectory (when their speed slows). This results in a sharp and localized peak of dose, known as the Bragg peak.
Proton beam therapy for tumors of skull baseTehreem Khan
This document discusses proton beam therapy for treating skull base tumors. It begins with an overview of brain tumors and skull base anatomy. It then discusses how tumors are diagnosed and different radiation therapy options. Proton beam therapy is introduced as an advanced form of radiation therapy that uses proton beams to damage tumor DNA. Key advantages are its ability to deposit most energy in the tumor while minimizing damage to surrounding healthy tissue. The document provides background on proton physics and accelerators used in therapy. It concludes proton beam therapy has been safely and effectively used in thousands of patients with various cancer types.
This document discusses radiation therapy for cancer treatment. It describes how the type of cancer, efficacy of other treatments, and patient health determine whether radiation therapy is used. Radiation therapy aims to kill cancer cells using high energy x-rays directed at tumors. Treatment planning involves outlining tumor volumes and minimizing dose to healthy tissues. Radiation damages DNA and prevents cell division, preferentially killing cancer cells. Modern linear accelerators precisely deliver megavoltage x-rays while minimizing surface dose. Treatment techniques like IMRT further improve targeting and reduce side effects.
The International Agency for Research on Cancer projects that by 2030 almost 21.4 million new cancer cases will be diagnosed annually, a sharp rise from the estimated 12.7 million new cases in 2008. The agency predicts that cancer rates will continue rising as populations increase and expand in developing nations.
Proton beam therapy uses protons to treat cancer. It can reduce the dose to healthy tissues compared to photon therapy by depositing most of the energy at a specific depth. Proton therapy has potential applications in tumors near critical structures where dose escalation may improve outcomes. However, more evidence from controlled trials is still needed to demonstrate comparative effectiveness versus other radiation therapies.
Radiation therapy uses ionizing radiation to treat cancer by damaging DNA in cancer cells to cause cell death. It works through direct damage to cancer cell DNA or indirectly by producing free radicals that damage DNA. Fractionated doses are used to allow normal cells time to recover while continuing to damage cancer cells. Complications can include skin damage, mouth sores, infertility, and long term risks like leukemia. Precise targeting and fractionation aims to maximize cancer cell killing while minimizing harm to surrounding normal tissues.
This trial will provide important level 1 evidence on the clinical benefits of protons for NSCLC. The primary outcomes of local control and toxicity will help determine if protons represent an improvement over IMRT. This type of comparative effectiveness trial is needed to fully evaluate new technologies like protons.
4
Future Directions
Continued improvements in proton delivery technology
Development of integrated PET/MRI for proton therapy
Advances in motion management and adaptive techniques
Combining protons with immunotherapy and targeted agents
Large, prospective comparative effectiveness trials
International data registries and collaborative research
Standardization of outcomes assessment and reporting
This presentation provides an overview of proton therapy, including its definition, history, mechanism, and applications. Proton therapy uses a beam of protons to treat cancerous tumors. It was first suggested in 1941 and the first treatment occurred in 1954. Proton therapy offers advantages over other treatments by depositing most of the radiation dose within the tumor and minimizing exposure of surrounding healthy tissue. Common applications include brain tumors and tumors located near critical organs. While proton therapy is effective, the equipment required is very expensive to build and operate.
Proton Beam Therapy for Prostate Cancer An Overviewijtsrd
Patients diagnosed with localized prostate cancer have many curative treatment options including several forms of advanced conformal Radiotherapy. Proton radiation is one such radiation treatment modality and, due to its unique physical properties, offers the appealing potential of reduced side effects without sacrificing cancer control. Patients of proton beam therapy PBT for prostate cancer had been continuously growing in number due to its promising characteristics of high dose distribution in the tumor target and a sharp distal fall-off. While theoretically beneficial, its clinical values are still being demonstrated from the increasing number of patients treated with proton therapy, from several dozen proton therapy centers around the world. High equipment and facility costs are often the major obstacle for its wider adoption. The picture will be clearer in coming decade as more and more centers throughout the world avail access to this technique and more data emerges on PBT. Suhag V | Sunita BS | Vats P "Proton Beam Therapy for Prostate Cancer: An Overview" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-2 , February 2019, URL: https://www.ijtsrd.com/papers/ijtsrd21439.pdf
Paper URL: https://www.ijtsrd.com/medicine/oncology/21439/proton-beam-therapy-for-prostate-cancer-an-overview/suhag-v
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
Therapeutic nuclear medicine uses radionuclides to treat various conditions like hyperthyroidism and thyroid cancer. Common isotopes used include iodine-131, phosphorus-32, and strontium-89. Administration procedures and internal dosimetry calculations are important considerations. The MIRD formalism provides a framework for calculating absorbed dose to target regions from radioactive sources. Key factors include cumulative activity, residence time, and absorbed fraction. Assumptions of uniform activity distribution and average absorbed dose are limitations but the MIRD approach is simple and easy to use.
Essentials of radiation therapy and cancer immunotherapy by Dr. Basil TumainiBasil Tumaini
Radiation therapy uses high-energy radiation to treat cancer and control its symptoms. It works by damaging DNA in cancer cells and preventing them from reproducing. The radiation oncology team includes radiation oncologists, medical physicists, dosimetrists, radiation therapists and nurses. Treatment involves simulation, planning and delivery, with the goal of maximizing dose to the tumor while minimizing it to healthy tissues. External beam radiation uses linear accelerators to deliver photon or particle beams in precise fractions over weeks, while brachytherapy places radioactive sources directly in or near tumors. New techniques like IMRT and SBRT further improve targeting accuracy.
Proton therapy is a type of particle therapy that uses a beam of protons to treat cancerous tumors. Protons deposit most of their energy at the tumor site in a phenomenon known as the Bragg peak, which allows for high radiation doses to be delivered to the tumor while minimizing exposure of surrounding healthy tissue. Proton therapy offers advantages over photon therapy for tumors located near critical structures due to its ability to more precisely target the tumor site. While proton therapy is an effective treatment, it requires highly specialized and expensive equipment and its use is currently limited to treating certain cancer types. However, its use is expected to grow as costs decrease and more treatment centers are established.
Principles of Radiotherapy in Head & Neck Surgery and Recent Advances A by Dr...Aditya Tiwari
This document provides an overview of radiotherapy principles for head and neck cancer. It discusses that head and neck cancer represents 6% of new cancer cases worldwide and radiotherapy plays an important role in its treatment. It then summarizes the brief history of radiotherapy and different radiation types used including photon beams, electron beams, and particle radiation. The document also covers radiotherapy techniques such as external beam radiotherapy using linear accelerators, brachytherapy, and fractionation schemes.
Proton therapy is an advanced form of particle therapy that uses a beam of protons to treat cancer. It more precisely targets radiation dosage to the tumor compared to other radiotherapy. Proton accelerators produce protons with energies between 70-250 MeV that cause DNA damage only in the targeted cells, sparing nearby tissue. Protons deposit most of their energy at the "Bragg peak" at the end of their range, penetrating no further. This allows proton therapy to avoid side effects of standard radiation and make it preferable for pediatric cases. While preliminary studies show few side effects, it remains the most precise radiation treatment available.
Nuclear medicine uses radioactive isotopes to provide diagnostic information about organ function and treat diseases. Diagnostic techniques involve injecting radioactive tracers that emit gamma rays and accumulate in organs, allowing imaging. Positron emission tomography (PET) uses isotopes produced in cyclotrons to provide precise images. Common isotopes used include technetium-99m for bone and heart imaging, iodine-131 for thyroid conditions, and fluorine-18 in PET scans to detect cancers. Therapeutic radiopharmaceuticals can also be used to destroy malfunctioning cells through beta radiation localization.
The document discusses proton beam radiotherapy and its advantages over traditional x-ray radiotherapy. It describes the equipment used for proton beam therapy including cyclotrons, treatment rooms with rotating gantries, patient immobilization devices, and beam shaping tools. It also provides examples of treatment plans comparing proton and x-ray intensity modulated radiotherapy for tumors in brain and spine.
The document discusses the use of high-energy protons in cancer therapy. It provides a history of proton beam therapy beginning in 1946 when Robert Wilson first suggested its use. It describes the first proton treatment centers and worldwide growth of proton therapy facilities. Key advantages of protons over photons discussed include lower entrance dose and maximum dose at tumor depth. Challenges and uncertainties in proton therapy planning and delivery are also summarized.
This slide includes physical, biological properties of proton and its advantage over the photon. It also provides information from beam production to treatment planning system of proton therapy, its potential applications, cost effectiveness and demerits.
Proton therapy uses protons to treat cancer. Protons deposit most of their energy at a specific depth, called the Bragg peak. This allows doctors to precisely target the tumor while minimizing radiation exposure to surrounding healthy tissue. Proton therapy is used to treat many types of cancers in the brain, head and neck region, lung, prostate, and other areas. It provides dosimetric advantages over photon therapy by reducing radiation doses to nearby critical structures like optic nerves and the spinal cord.
This document discusses the history and techniques of precision radiotherapy. It describes how radiotherapy has evolved from early X-ray units to modern linear accelerators and proton therapy. The goals of radiotherapy treatment are to deliver a cancer-killing dose to the tumor volume while avoiding or minimizing radiation to critical structures, in order to improve quality of life. Modern techniques like IMRT, IGRT, and SRS allow for more precise targeting of tumors and sparing of surrounding healthy tissue through the use of imaging, treatment planning, quality assurance, and verification processes.
This document discusses the biological aspects and principles of radiation therapy. It begins by covering how radiation induces DNA damage through direct interaction or free radical production. It then describes the cellular responses, including cell cycle checkpoints, DNA repair pathways, and membrane signaling. Chromosomal aberrations from faulty DNA repair can lead to cell death. The effects of radiation on cell survival are also reviewed, such as apoptosis or delayed reproductive cell death. Factors like the 4 R's (repair, reassortment, repopulation, reoxygenation) that influence radiation response are also summarized.
MIT User Center for Neutron Capture Therapy Resarchkent.riley
The MIT User Center for Neutron Capture Therapy Research provides specialized facilities and capabilities to support preclinical and clinical research in neutron capture therapy (NCT). The Center has two neutron beam facilities located at the Massachusetts Institute of Technology Research Reactor - a thermal neutron beam well-suited for small animal and cell culture studies, and an epithermal beam for clinical studies. Researchers can access these beams as well as capabilities like boron analysis, dosimetry, cell and animal research labs. The Center aims to support the widespread international effort to develop NCT as an effective cancer treatment.
Proton beam therapy uses protons to treat cancer. It can reduce the dose to healthy tissues compared to photon therapy by depositing most of the energy at a specific depth. Proton therapy has potential applications in tumors near critical structures where dose escalation may improve outcomes. However, more evidence from controlled trials is still needed to demonstrate comparative effectiveness versus other radiation therapies.
Radiation therapy uses ionizing radiation to treat cancer by damaging DNA in cancer cells to cause cell death. It works through direct damage to cancer cell DNA or indirectly by producing free radicals that damage DNA. Fractionated doses are used to allow normal cells time to recover while continuing to damage cancer cells. Complications can include skin damage, mouth sores, infertility, and long term risks like leukemia. Precise targeting and fractionation aims to maximize cancer cell killing while minimizing harm to surrounding normal tissues.
This trial will provide important level 1 evidence on the clinical benefits of protons for NSCLC. The primary outcomes of local control and toxicity will help determine if protons represent an improvement over IMRT. This type of comparative effectiveness trial is needed to fully evaluate new technologies like protons.
4
Future Directions
Continued improvements in proton delivery technology
Development of integrated PET/MRI for proton therapy
Advances in motion management and adaptive techniques
Combining protons with immunotherapy and targeted agents
Large, prospective comparative effectiveness trials
International data registries and collaborative research
Standardization of outcomes assessment and reporting
This presentation provides an overview of proton therapy, including its definition, history, mechanism, and applications. Proton therapy uses a beam of protons to treat cancerous tumors. It was first suggested in 1941 and the first treatment occurred in 1954. Proton therapy offers advantages over other treatments by depositing most of the radiation dose within the tumor and minimizing exposure of surrounding healthy tissue. Common applications include brain tumors and tumors located near critical organs. While proton therapy is effective, the equipment required is very expensive to build and operate.
Proton Beam Therapy for Prostate Cancer An Overviewijtsrd
Patients diagnosed with localized prostate cancer have many curative treatment options including several forms of advanced conformal Radiotherapy. Proton radiation is one such radiation treatment modality and, due to its unique physical properties, offers the appealing potential of reduced side effects without sacrificing cancer control. Patients of proton beam therapy PBT for prostate cancer had been continuously growing in number due to its promising characteristics of high dose distribution in the tumor target and a sharp distal fall-off. While theoretically beneficial, its clinical values are still being demonstrated from the increasing number of patients treated with proton therapy, from several dozen proton therapy centers around the world. High equipment and facility costs are often the major obstacle for its wider adoption. The picture will be clearer in coming decade as more and more centers throughout the world avail access to this technique and more data emerges on PBT. Suhag V | Sunita BS | Vats P "Proton Beam Therapy for Prostate Cancer: An Overview" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-2 , February 2019, URL: https://www.ijtsrd.com/papers/ijtsrd21439.pdf
Paper URL: https://www.ijtsrd.com/medicine/oncology/21439/proton-beam-therapy-for-prostate-cancer-an-overview/suhag-v
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
Therapeutic nuclear medicine uses radionuclides to treat various conditions like hyperthyroidism and thyroid cancer. Common isotopes used include iodine-131, phosphorus-32, and strontium-89. Administration procedures and internal dosimetry calculations are important considerations. The MIRD formalism provides a framework for calculating absorbed dose to target regions from radioactive sources. Key factors include cumulative activity, residence time, and absorbed fraction. Assumptions of uniform activity distribution and average absorbed dose are limitations but the MIRD approach is simple and easy to use.
Essentials of radiation therapy and cancer immunotherapy by Dr. Basil TumainiBasil Tumaini
Radiation therapy uses high-energy radiation to treat cancer and control its symptoms. It works by damaging DNA in cancer cells and preventing them from reproducing. The radiation oncology team includes radiation oncologists, medical physicists, dosimetrists, radiation therapists and nurses. Treatment involves simulation, planning and delivery, with the goal of maximizing dose to the tumor while minimizing it to healthy tissues. External beam radiation uses linear accelerators to deliver photon or particle beams in precise fractions over weeks, while brachytherapy places radioactive sources directly in or near tumors. New techniques like IMRT and SBRT further improve targeting accuracy.
Proton therapy is a type of particle therapy that uses a beam of protons to treat cancerous tumors. Protons deposit most of their energy at the tumor site in a phenomenon known as the Bragg peak, which allows for high radiation doses to be delivered to the tumor while minimizing exposure of surrounding healthy tissue. Proton therapy offers advantages over photon therapy for tumors located near critical structures due to its ability to more precisely target the tumor site. While proton therapy is an effective treatment, it requires highly specialized and expensive equipment and its use is currently limited to treating certain cancer types. However, its use is expected to grow as costs decrease and more treatment centers are established.
Principles of Radiotherapy in Head & Neck Surgery and Recent Advances A by Dr...Aditya Tiwari
This document provides an overview of radiotherapy principles for head and neck cancer. It discusses that head and neck cancer represents 6% of new cancer cases worldwide and radiotherapy plays an important role in its treatment. It then summarizes the brief history of radiotherapy and different radiation types used including photon beams, electron beams, and particle radiation. The document also covers radiotherapy techniques such as external beam radiotherapy using linear accelerators, brachytherapy, and fractionation schemes.
Proton therapy is an advanced form of particle therapy that uses a beam of protons to treat cancer. It more precisely targets radiation dosage to the tumor compared to other radiotherapy. Proton accelerators produce protons with energies between 70-250 MeV that cause DNA damage only in the targeted cells, sparing nearby tissue. Protons deposit most of their energy at the "Bragg peak" at the end of their range, penetrating no further. This allows proton therapy to avoid side effects of standard radiation and make it preferable for pediatric cases. While preliminary studies show few side effects, it remains the most precise radiation treatment available.
Nuclear medicine uses radioactive isotopes to provide diagnostic information about organ function and treat diseases. Diagnostic techniques involve injecting radioactive tracers that emit gamma rays and accumulate in organs, allowing imaging. Positron emission tomography (PET) uses isotopes produced in cyclotrons to provide precise images. Common isotopes used include technetium-99m for bone and heart imaging, iodine-131 for thyroid conditions, and fluorine-18 in PET scans to detect cancers. Therapeutic radiopharmaceuticals can also be used to destroy malfunctioning cells through beta radiation localization.
The document discusses proton beam radiotherapy and its advantages over traditional x-ray radiotherapy. It describes the equipment used for proton beam therapy including cyclotrons, treatment rooms with rotating gantries, patient immobilization devices, and beam shaping tools. It also provides examples of treatment plans comparing proton and x-ray intensity modulated radiotherapy for tumors in brain and spine.
The document discusses the use of high-energy protons in cancer therapy. It provides a history of proton beam therapy beginning in 1946 when Robert Wilson first suggested its use. It describes the first proton treatment centers and worldwide growth of proton therapy facilities. Key advantages of protons over photons discussed include lower entrance dose and maximum dose at tumor depth. Challenges and uncertainties in proton therapy planning and delivery are also summarized.
This slide includes physical, biological properties of proton and its advantage over the photon. It also provides information from beam production to treatment planning system of proton therapy, its potential applications, cost effectiveness and demerits.
Proton therapy uses protons to treat cancer. Protons deposit most of their energy at a specific depth, called the Bragg peak. This allows doctors to precisely target the tumor while minimizing radiation exposure to surrounding healthy tissue. Proton therapy is used to treat many types of cancers in the brain, head and neck region, lung, prostate, and other areas. It provides dosimetric advantages over photon therapy by reducing radiation doses to nearby critical structures like optic nerves and the spinal cord.
This document discusses the history and techniques of precision radiotherapy. It describes how radiotherapy has evolved from early X-ray units to modern linear accelerators and proton therapy. The goals of radiotherapy treatment are to deliver a cancer-killing dose to the tumor volume while avoiding or minimizing radiation to critical structures, in order to improve quality of life. Modern techniques like IMRT, IGRT, and SRS allow for more precise targeting of tumors and sparing of surrounding healthy tissue through the use of imaging, treatment planning, quality assurance, and verification processes.
This document discusses the biological aspects and principles of radiation therapy. It begins by covering how radiation induces DNA damage through direct interaction or free radical production. It then describes the cellular responses, including cell cycle checkpoints, DNA repair pathways, and membrane signaling. Chromosomal aberrations from faulty DNA repair can lead to cell death. The effects of radiation on cell survival are also reviewed, such as apoptosis or delayed reproductive cell death. Factors like the 4 R's (repair, reassortment, repopulation, reoxygenation) that influence radiation response are also summarized.
MIT User Center for Neutron Capture Therapy Resarchkent.riley
The MIT User Center for Neutron Capture Therapy Research provides specialized facilities and capabilities to support preclinical and clinical research in neutron capture therapy (NCT). The Center has two neutron beam facilities located at the Massachusetts Institute of Technology Research Reactor - a thermal neutron beam well-suited for small animal and cell culture studies, and an epithermal beam for clinical studies. Researchers can access these beams as well as capabilities like boron analysis, dosimetry, cell and animal research labs. The Center aims to support the widespread international effort to develop NCT as an effective cancer treatment.
This document provides a critical review of fission reactor neutron sources for neutron capture therapy (NCT). It summarizes that epithermal neutron beams, favored for treating deep tumors, have been constructed or are being constructed at several reactors worldwide, with some newer beams approaching theoretical optimum purity. At least one such high-quality beam is suitable for routine therapy. Reactor-based epithermal beams with near-optimum characteristics are currently available and more can be constructed. Suitable reactors include low-power reactors using the core directly or a fission converter as the neutron source. Thermal neutron beams have also been available for years with near-optimum properties for small animal studies or shallow tumors.
This document summarizes the key aspects of characterizing the neutron beam facility at iThemba LABS. It describes the neutron production process using various targets like lithium, beryllium, and carbon. Time of flight measurements can be performed by increasing the time between proton bunches. The neutron beam is characterized using detectors like a fission chamber, organic scintillators, and a NE102 detector. Metrological issues like monitoring beam stability, determining beam profiles, and accounting for parasitic neutrons are also discussed.
This lecture discusses several topics in nanotechnology including fuel cells, nano-composite materials, nanoelectronics, photonic devices, chemical and biological detectors, and applications in nanomedicine. Specifically, the lecture covers:
1) Fuel cells and the advantages of using nanomaterials like membranes and catalysts to improve efficiency.
2) Nano-composite materials and their use in applications like reinforced composites with nanotubes or nanoparticles.
3) Nanoelectronic and photonic devices like transistors, photonic crystals, and integrated photonics.
4) Chemical and biological detectors using techniques like microarrays, carbon nanotubes, and surface plasmon resonance.
5) Applications in nan
This document summarizes research on amphiphiles and Langmuir monolayers. It discusses how amphiphiles are composed of a hydrophilic head and hydrophobic tail. When spread on water, amphiphiles form Langmuir monolayers where the heads interact with water and tails with air. Pressure-area isotherms of these monolayers show phase transitions as pressure increases. Adding metal ions to the water subphase can induce superlattice formation underneath the monolayer. Studies using x-ray diffraction and other techniques characterized the structures of various Langmuir monolayers and how they change with conditions like subphase pH and metal ion type.
The document summarizes the conception, construction, and testing of LIBO, a prototype linear accelerator module for a compact proton therapy facility. Key points:
- LIBO is a side-coupled linear accelerator structure operating at 3 GHz designed to boost the energy of a proton beam from 62 MeV to 200 MeV for cancer therapy applications.
- The design and construction of a prototype LIBO module is described, including the half-cell design, material selection, thermal stabilization, bridge couplers, and integration of permanent magnet quadrupoles.
- The prototype module was machined at CERN using numerical control and its components were brazed together under vacuum. RF measurements validated the electric field flatness was within 3
Carbon nanotube sensors are promising due to their unique properties like electrical conductivity and strength. The document discusses different types of carbon nanotube sensors including gas ionization sensors that detect gases by measuring breakdown voltage. Emerging applications include chemical sensors using carbon nanotube field effect transistors coated with DNA to detect toxins. Future directions include developing intelligent sensors that can optimize themselves and wireless sensors incorporated into robotic fish to detect pollution in the environment.
Preparative mass spectrometry was developed during World War II as part of the Manhattan Project to separate uranium isotopes for nuclear weapons. It uses mass spectrometry techniques like calutrons to separate isotopes based on their mass-to-charge ratios. Today, preparative mass spectrometry has applications in areas like biomedical research, cancer treatment, and purification of biomolecules. It is used for both large-scale isotope separation as well as targeted deposition of molecules through soft landing techniques.
Performance Characteristics of the MIT Epithermal Neutron Irradiation Facilitykent.riley
This document summarizes the performance characteristics of the first fission converter-based epithermal neutron beam (FCB) designed for boron neutron capture therapy (BNCT) at the Massachusetts Institute of Technology (MIT). Key findings include:
1) The FCB provides an epithermal neutron flux of 4.6 × 109 n cm-2 s-1, making it the most intense BNCT source in the world. It achieves low specific photon and fast neutron absorbed doses.
2) Measurements confirm the beam achieves a therapeutic dose rate of 1.7 RBE Gy min-1 at a depth of 97 mm using boronated phenylalanine, with an average therapeutic ratio of
Lithium Filtration for Improved Dose Penetration in BNCTkent.riley
This document summarizes research into adding an optional 6Li filter to an existing epithermal neutron beam used for boron neutron capture therapy (BNCT) to treat brain tumors. Monte Carlo simulations and measurements were used to design and test a removable 8mm thick 6Li filter. The filter improved penetration of thermal neutrons to depths of 9.9cm while maintaining tumor selectivity. Recalculating past treatment plans showed the filter could increase minimum deliverable tumor doses by up to 9% without increasing normal tissue doses. The filter provides an incremental enhancement to the clinical beam that may help establish a therapeutic window for treating deeper tumors.
This E-nano Newsletter special double issue
contains the updated version of the nanoICT
position paper on Carbon Nanotubes (CNTs)
summarising state-of-the-art research in this field
as well as a description of the possible electrical,
electronic and photonic applications of carbon
nanotubes, the types of CNTs employed and the
organisations or groups that are most proficient
at fabricating them.
In the second paper, the Nanoelectronics
European Research Roadmap is addressed
focusing on the main European Programmes
supporting the short, medium and long-term
research activities.
This issue also contains a catalogue (insert),
compiled by the Phantoms Foundation
providing a general overview of the
Nanoscience and Nanotechnology
companies in Spain and in particular the
importance of this market research,
product development, etc.
We would like to thank all the authors
who contributed to this issue as well as
the European Commission for the
financial support (project nanoICT No.
216165).
Dr. Antonio Correia
Editor - Phantoms Foundation
www.phantomsnet.net
Radiopharmaceutical is topic of subject Pharmaceutical inorganic Chemistry for B. Pharmacy First year students. This slide is presented with an aim to enable the students to easily understand and grasp unfamiliar concept of this topic
This document discusses the use of gamma-ray computed tomography (CT) to image and quantify internal distributions of phases in multiphase reactors and flow systems. A dual-source gamma-ray CT scanner developed at Oak Ridge National Laboratory was used. This technique involves rotating gamma ray sources and detectors around an object to perform CT scans and has been applied successfully to study multiphase flow systems. The dimensions of collimators for the gamma ray sources and detectors were designed to provide enough open area and acquire counts with high signal-to-noise ratio.
This document discusses the motivation for using antiprotons in cancer therapy. It provides background on hadron therapy and its advantages over traditional photon therapy. Charged particles like protons and carbon ions deposit most of their energy at the end of their range, allowing for precise dose delivery to tumors. Antiprotons offer additional advantages - their annihilation with tissue releases additional energy, potentially allowing lower particle numbers to treat tumors. This energy is deposited locally. Antiprotons also produce pions during annihilation, enabling real-time tracking of the irradiation. However, antiproton availability is limited to only two facilities worldwide. The document introduces the Antiproton Cell Experiment (ACE) which researches antiproton therapy and describes the goal of
- There are two main systems for measuring radiation - the conventional US system and the International System of Units (SI).
- Radioactivity is measured in curies (Ci) in the US system and becquerels (Bq) in the SI system. 1 Ci equals 37 billion Bq.
- Exposure rate is measured in roentgens (R) per hour in the US system. The SI unit is the coulomb per kilogram (C/kg).
- Absorbed dose is measured in rads in the US system and grays (Gy) in the SI system. 1 Gy is equal to 100 rads.
Nuclear medicine uses small amounts of radioactive tracers to diagnose and treat disease. Tracers are injected into patients and accumulate in organs, with uptake indicating healthy or diseased tissue. Imaging modalities like PET and SPECT detect radiation from tracers to create functional images of the inside of the body. Nuclear medicine provides high sensitivity to detect conditions like cancer and heart disease. It differs from CT and MRI which show anatomical structure.
The document discusses several topics related to nanomaterials and their applications including:
- Various nanomaterials being researched for applications in electronics, energy, biomedical and other fields.
- Challenges in controlling the size and shape of nanomaterials during synthesis and scaling up production.
- Use of reverse micelles and other methods to synthesize nanoparticles and control their properties.
- Applications of nanomaterials in areas like solar cells, drug delivery, biosensing, catalysis, and electronics.
- Ongoing research on graphene and other emerging nanomaterials and their potential future applications.
Presentation on energy iter2017 januaryCooper Lackay
This document provides an overview of nuclear fusion and the ITER (International Thermonuclear Experimental Reactor) project. It describes how ITER aims to demonstrate the scientific and technological feasibility of fusion power by producing 500 megawatts of power sustained for long periods using the tokamak design. Key challenges for ITER include materials issues from high heat and particle loads as well as producing tritium fuel on-site, but proposed solutions could help address these challenges. If successful, ITER will bring the world closer to developing fusion as a safe, clean, and virtually limitless source of energy.
This document provides an overview of various medical imaging and treatment techniques. It discusses diagnostic techniques like X-rays, CT scans, PET scans, ultrasound, MRI, and endoscopy. It explains how each works, such as how X-rays are produced via interactions between electrons and a tungsten target, and how PET scans detect gamma ray pairs to construct 3D images. The document also includes a quiz testing knowledge of these different imaging modalities.
international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea
international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea
international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea
international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea international workshop accelerator based neutron sources for medical industrial and scientific applications torino eurosea
Dr. Sean Tan, Head of Data Science, Changi Airport Group
Discover how Changi Airport Group (CAG) leverages graph technologies and generative AI to revolutionize their search capabilities. This session delves into the unique search needs of CAG’s diverse passengers and customers, showcasing how graph data structures enhance the accuracy and relevance of AI-generated search results, mitigating the risk of “hallucinations” and improving the overall customer journey.
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!SOFTTECHHUB
As the digital landscape continually evolves, operating systems play a critical role in shaping user experiences and productivity. The launch of Nitrux Linux 3.5.0 marks a significant milestone, offering a robust alternative to traditional systems such as Windows 11. This article delves into the essence of Nitrux Linux 3.5.0, exploring its unique features, advantages, and how it stands as a compelling choice for both casual users and tech enthusiasts.
In the rapidly evolving landscape of technologies, XML continues to play a vital role in structuring, storing, and transporting data across diverse systems. The recent advancements in artificial intelligence (AI) present new methodologies for enhancing XML development workflows, introducing efficiency, automation, and intelligent capabilities. This presentation will outline the scope and perspective of utilizing AI in XML development. The potential benefits and the possible pitfalls will be highlighted, providing a balanced view of the subject.
We will explore the capabilities of AI in understanding XML markup languages and autonomously creating structured XML content. Additionally, we will examine the capacity of AI to enrich plain text with appropriate XML markup. Practical examples and methodological guidelines will be provided to elucidate how AI can be effectively prompted to interpret and generate accurate XML markup.
Further emphasis will be placed on the role of AI in developing XSLT, or schemas such as XSD and Schematron. We will address the techniques and strategies adopted to create prompts for generating code, explaining code, or refactoring the code, and the results achieved.
The discussion will extend to how AI can be used to transform XML content. In particular, the focus will be on the use of AI XPath extension functions in XSLT, Schematron, Schematron Quick Fixes, or for XML content refactoring.
The presentation aims to deliver a comprehensive overview of AI usage in XML development, providing attendees with the necessary knowledge to make informed decisions. Whether you’re at the early stages of adopting AI or considering integrating it in advanced XML development, this presentation will cover all levels of expertise.
By highlighting the potential advantages and challenges of integrating AI with XML development tools and languages, the presentation seeks to inspire thoughtful conversation around the future of XML development. We’ll not only delve into the technical aspects of AI-powered XML development but also discuss practical implications and possible future directions.
Threats to mobile devices are more prevalent and increasing in scope and complexity. Users of mobile devices desire to take full advantage of the features
available on those devices, but many of the features provide convenience and capability but sacrifice security. This best practices guide outlines steps the users can take to better protect personal devices and information.
Maruthi Prithivirajan, Head of ASEAN & IN Solution Architecture, Neo4j
Get an inside look at the latest Neo4j innovations that enable relationship-driven intelligence at scale. Learn more about the newest cloud integrations and product enhancements that make Neo4j an essential choice for developers building apps with interconnected data and generative AI.
In his public lecture, Christian Timmerer provides insights into the fascinating history of video streaming, starting from its humble beginnings before YouTube to the groundbreaking technologies that now dominate platforms like Netflix and ORF ON. Timmerer also presents provocative contributions of his own that have significantly influenced the industry. He concludes by looking at future challenges and invites the audience to join in a discussion.
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfPaige Cruz
Monitoring and observability aren’t traditionally found in software curriculums and many of us cobble this knowledge together from whatever vendor or ecosystem we were first introduced to and whatever is a part of your current company’s observability stack.
While the dev and ops silo continues to crumble….many organizations still relegate monitoring & observability as the purview of ops, infra and SRE teams. This is a mistake - achieving a highly observable system requires collaboration up and down the stack.
I, a former op, would like to extend an invitation to all application developers to join the observability party will share these foundational concepts to build on:
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?Speck&Tech
ABSTRACT: A prima vista, un mattoncino Lego e la backdoor XZ potrebbero avere in comune il fatto di essere entrambi blocchi di costruzione, o dipendenze di progetti creativi e software. La realtà è che un mattoncino Lego e il caso della backdoor XZ hanno molto di più di tutto ciò in comune.
Partecipate alla presentazione per immergervi in una storia di interoperabilità, standard e formati aperti, per poi discutere del ruolo importante che i contributori hanno in una comunità open source sostenibile.
BIO: Sostenitrice del software libero e dei formati standard e aperti. È stata un membro attivo dei progetti Fedora e openSUSE e ha co-fondato l'Associazione LibreItalia dove è stata coinvolta in diversi eventi, migrazioni e formazione relativi a LibreOffice. In precedenza ha lavorato a migrazioni e corsi di formazione su LibreOffice per diverse amministrazioni pubbliche e privati. Da gennaio 2020 lavora in SUSE come Software Release Engineer per Uyuni e SUSE Manager e quando non segue la sua passione per i computer e per Geeko coltiva la sua curiosità per l'astronomia (da cui deriva il suo nickname deneb_alpha).
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...Neo4j
Leonard Jayamohan, Partner & Generative AI Lead, Deloitte
This keynote will reveal how Deloitte leverages Neo4j’s graph power for groundbreaking digital twin solutions, achieving a staggering 100x performance boost. Discover the essential role knowledge graphs play in successful generative AI implementations. Plus, get an exclusive look at an innovative Neo4j + Generative AI solution Deloitte is developing in-house.
Generative AI Deep Dive: Advancing from Proof of Concept to ProductionAggregage
Join Maher Hanafi, VP of Engineering at Betterworks, in this new session where he'll share a practical framework to transform Gen AI prototypes into impactful products! He'll delve into the complexities of data collection and management, model selection and optimization, and ensuring security, scalability, and responsible use.
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slackshyamraj55
Discover the seamless integration of RPA (Robotic Process Automation), COMPOSER, and APM with AWS IDP enhanced with Slack notifications. Explore how these technologies converge to streamline workflows, optimize performance, and ensure secure access, all while leveraging the power of AWS IDP and real-time communication via Slack notifications.
1. Accelerator-based versus Reactor-based neutron sources for BNCT – an ISNCT perspective Ray Moss (Secretary/Treasurer ISNCT) Sector Leader Medical Applications, High Flux Reactor Unit, Institute for Energy, Joint Research Centre, Petten, The Netherlands
3. ISNCT ISNCT CONSTITUTION Article I NAME OF SOCIETY The organization shall be called The International Society for Neutron Capture Therapy . Article II PURPOSE OF SOCIETY The purpose of the Society shall be to promote widespread interest in neutron capture therapy and related forms of management of cancer and other diseases with present emphasis on neutron capture therapy. This promotion includes the holding of scientific meetings and other such endeavors as seen appropriate to the Executive Board.
4. 1st 12-14 October 1983 Cambridge, MA, USA Brownell/Fairchild 2nd 18 - 20 October 1985 Tokyo,Japan Hiroshi Hatanaka 3rd 31 May - 3 June 1988 Bremen, Germany Detlef Gabel 4th 4-7 December 1990 Sydney, Australia Barry J. Allen 5th 14-17 September 1992 Columbus, OH, USA Albert J. Soloway 6th 31 October - 4 November 1994 Kobe, Japan Yutaka Mishima 7th 4-7 September 1996 Zurich, Switzerland Börje Larsson 8th 13-18 September 1998 La Jolla, CA, USA Fred Hawthorne 9th 2 – 6 October 2000 Osaka, Japan Keiji Kanda 10th 8- 13 September 2002 Essen, Germany W. Sauerwein 11th 11-15 October 2004 Boston, USA Robert Zamenhof 12th 9-13 October 2006 Takamatsu, Japan Yoshi Nakagawa 13th 2-7 November 2008 Florence, Italy Aris Zonta Biennial Congresses on NCT
5. Committee for Standards in Dosimetry Committee for Standards & Protocols in Clinical Trials Committee for Standards in Treatment Planning Committee for Financial Auditing Committee for Standards in Accelerators Committees on NCT
6. BNCT is based on the ability of the isotope 10 B to capture low energy neutrons to produce two highly energetic particles with low range in tissue. What is BNCT ? Boron Neutron Capture Therapy gamma 0.48 MeV 10 B 0.84 MeV 7 Li 1.47 MeV 4 He(alpha) n th
7.
8.
9.
10. Present Neutron Beams used in BNCT 2. JRR-4 (JAERI) 1998 [>10, glioma, meningioma] 3. KUR, Kyoto, Japan 1998 [>50 head and neck] 3. VTT, Finland 1999 [>100, now mainly head and neck] 4. Rez, Czech Rep. 2000 [5, glioblastoma] 5. Studsvik, Sweden 2001 [>40] 6. MIT, USA 2002 [7] 7. Pavia, Italy 2001 [2, extracorporeal liver] 8. Bariloche, Argentina 2003 [3, skin melanoma] 9. THOR, Taiwan 2008 10.HANORA, S. Korea 2008 Generation 4: new generation 1. HFR Petten 1997 [26-glioblastoma, 4-melanoma metastases] With imminent closure?? ALL using nuclear research reactors
11. Status ??? Recent results (ICNCT 2006) Both in Japan (Osaka University) and Finland (Helsinki), successful treatment of Head and Neck cancers. Finns also showed good results for recurrent glioblastoma. Argentina reported on the successful treatment of multinodular skin melanoma (3 patients). Japan reports on successful BNCT for Cutaneous and Mucosal melanoma. Japan (Tsukuba) results of a combined photon + BNCT study (glioblastoma), the outcome is very good. Other studies for the treatment of thyroid cancer, melanoma and head and neck cancers (all in Japan).
14. Factors in beam design – Therapeutic gain - is defined as the ratio of the total dose in the tumour at depth to the maximum dose in the healthy tissue. epithermal neutrons utilise the overlying tissue to lose their energy, principally through elastic scatter with hydrogen nuclei, and become thermalised
15. “ SLOW” (THERMAL) NEUTRONS - low penetration in tissue - high reaction rate 10 B(n, ) 7 Li reaction “ FAST” (EPITHERMAL) NEUTRONS - high penetration in tissue - low reaction rate 10 B(n, ) 7 Li reaction Prague, 11-12 Nov 2005
16. Dose components in tissue, due to a reactor beam Neutron absorbed dose D n Gamma ray absorbed dose D g Nitrogen neutron capture absorbed dose D N Boron neutron capture absorbed dose D B
17.
18. Present Reactor-based Neutron Beams for BNCT Japan Atomic Energy Research Institute, Tokai , Ibaraki, Japan HFR Petten, Netherlands MIT, Boston, USA
19. Examples of materials used in beam designs for BNCT at various reactors Reactors Moderators Filters Attenuators BMRR H 2 O, C Al, Cd, Al 2 O 3 Bi MITR-II H 2 O, D 2 O Al, S, Cd, Li Bi, poly- 6 Li HFR H 2 O Al, Ti, S, Cd Ar, poly-B fission plate Al 2 O 3 , Al, H 2 O Al, LiF 3 Bi, Pb, 6 Li Mu.ITR Al, C, H 2 O Al, LiF 3 Bi TRIGA C, H 2 O LiF 3 Bi, Pb R2-0 Al, H 2 O/D 2 O Al, Li, teflon Bi, Pb, 6 Li FiR I (TRIGA) Al Fluental Bi
21. Is there an optimal approach ? Many variables Reactor type Tumour to be treated, size, location, depth ……. Boron compound to be used .............. Use of a variable, dynamic filter arrangement, producing a shift in neutron energy spectrum, changing neutron intensity, a rotating beam or patient,…………. Theoretically – Yes But practically ….No BNCT facility to suit the type of tumour to be treated
25. BNCT - HFR Petten The BNCT-Wing - arrival of patient
26.
27. Presentations at the last ICNCT 2006, Takamatsu, Japan Accelerator-based systems for BNCT IPPE, Korkachov, Russia Hanyang University, Seoul, South Korea Tohoku University, Japan IBA – dynamitron – Japan Hitachi – Japan CNEA, Argentina Budker INP, Novosibirsk, Russia KURR, Kyoto, Japan THE major problem is that nuclear reactors for BNCT use, are very unlikely to be built and located in a hospital – Accelerators already exist in hospitals!
28. The Medical Physics Building in Birmingham Cyclotron vault Dynamitron Protons Neutrons Li target, Beam moderator / shield
29. The actual treatment facility (mid 2003) Proton beam-tube Heavy water reservoir FLUENTAL TM moderator Li-polythene delimiter / shield Heavy water inlet To pumps / chiller Neutron source is > 1 x 10 12 s -1
31. In conclusion …… Reactor-based facilities have been used, and are still being used for BNCT, for over 50 years. Economical and logistical reasons – difficult to sustain Accelerator-based facilities are the future of BNCT BUT they must be able to demonstrate that the required beam characteristics can be achieved